2, 4 -di (arylaminio) - pyrimidine-5-carboxamide compounds as JAK kinases inhibitors

Details for Australian Patent Application No. 2007276369 (hide)

Owner Novartis AG

Inventors Zerwes, Hans-Gunter; Thoma, Gebhard; Walchli, Rudolf; Holzer, Philipp; Duthaler, Rudolf; Streiff, Markus; Gerspacher, Marc

Agent Davies Collison Cave

Pub. Number AU-A-2007276369

PCT Pub. Number WO2008/009458

Priority 06117632.7 21.07.06 EP

Filing date 19 July 2007

Wipo publication date 24 January 2008

International Classifications

C07D 239/48 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/505 (2006.01) - Pyrimidines

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

Event Publications

5 February 2009 PCT application entered the National Phase

  PCT publication WO2008/009458 Priority application(s): WO2008/009458

26 April 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007276381-Chiral compounds substituted with phosphonate ester or phosphonic acid

2007276318-Heterobicyclic carboxamides as inhibitors for kinases